Literature DB >> 11337039

HIV-1 subtyping using phylogenetic analysis of pol gene sequences.

C Pasquier1, N Millot, R Njouom, K Sandres, M Cazabat, J Puel, J Izopet.   

Abstract

HIV-1 pol gene sequencing is now used routinely in France to identify mutations associated with resistance to reverse transcriptase (RT) or protease (PR) inhibitors. These sequences may also provide other information, such as the HIV-1 subtype. HIV-1 subtyping was compared using the RT and PR gene sequences to heteroduplex mobility assay (HMA) of the envelope gene. The RT and PR genes of 51 samples that had been subtyped earlier by HMA were sequenced. Sequences were aligned and subtypes were determined by phylogenetic analysis with reference HIV sequences. HMA gave the following subtypes: A (20), B (19), C (1), D (3), F (1), G (3) and CRF01-AE (4). Phylogenetic analysis of the RT gene gave: A (5), B (19), C (2), D (3), F (1), G (6), J (2), CRF01_AE (4), CFR02_AG (7) and undetermined (2). PR gene analysis did not infer subtypes with sufficient confidence. HMA and RT subtyping was not in agreement in nine cases. RT subtyping can identify CFR02_AG and CRF01_AE variants from A subtype RT. It was shown that phylogenetic analysis of the RT gene could provide a useful method for HIV-1 subtyping. The length of the amplicon and the relative performance of each primer pair used in this study favoured RT sequences as a subtyping tool. One potential advantage over env subtyping HMA is the ability to identify some circulating recombinant forms (CRFs).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337039     DOI: 10.1016/s0166-0934(01)00272-5

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  20 in total

1.  Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.

Authors:  Boubacar Nacro; Emmanuelle Zoure; Hervé Hien; Hassane Tamboura; François Rouet; Adama Ouiminga; Ali Drabo; Souleymane Yameogo; Alain Hien; Hélène Peyriere; Olivier Mathieu; Deborah Hirt; Jean-Marc Treluyer; Joëlle Nicolas; Vincent Foulongne; Michel Segondy; Philippe van de Perre; Serge Diagbouga; Philippe Msellati
Journal:  Bull World Health Organ       Date:  2011-04-06       Impact factor: 9.408

2.  Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).

Authors:  Christophe Delaunay; Françoise Brun-Vézinet; Roland Landman; Gilles Collin; Gilles Peytavin; Aldo Trylesinski; Philippe Flandre; Michael Miller; Diane Descamps
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.

Authors:  Lavinia Fabeni; Giulia Berno; Joseph Fokam; Ada Bertoli; Claudia Alteri; Caterina Gori; Federica Forbici; Desiré Takou; Alessandra Vergori; Mauro Zaccarelli; Gaetano Maffongelli; Vanni Borghi; Alessandra Latini; Alfredo Pennica; Claudio Maria Mastroianni; Francesco Montella; Cristina Mussini; Massimo Andreoni; Andrea Antinori; Carlo Federico Perno; Maria Mercedes Santoro
Journal:  J Clin Microbiol       Date:  2017-07-12       Impact factor: 5.948

4.  Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting.

Authors:  Francois Rouet; Didier K Ekouevi; Marie-Laure Chaix; Marianne Burgard; Andre Inwoley; Thomas D'Aquin Tony; Christine Danel; Xavier Anglaret; Valeriane Leroy; Philippe Msellati; Francois Dabis; Christine Rouzioux
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

5.  Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Authors:  Eugène Messou; Marie-Laure Chaix; Delphine Gabillard; Albert Minga; Elena Losina; Vincent Yapo; Martial Kouakou; Christine Danel; Caroline Sloan; Christine Rouzioux; Kenneth A Freedberg; Xavier Anglaret
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

6.  Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

Authors:  Véronique Joly; Philippe Flandre; Vincent Meiffredy; Françoise Brun-Vezinet; Jean-Albert Gastaut; Cécile Goujard; Gérard Remy; Diane Descamps; Annick Ruffault; Agnès Certain; Jean-Pierre Aboulker; Patrick Yeni
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Field evaluation of the gag-based heteroduplex mobility assay for genetic subtyping of circulating recombinant forms of human immunodeficiency virus type 1 in Abidjan, Côte d'Ivoire.

Authors:  Souleymane Sawadogo; Christiane Adjé-Touré; Celestin E Bilé; Rene E A Ekpini; Terence Chorba; John N Nkengasong
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment.

Authors:  Tamara Nora; Charlotte Charpentier; Olivier Tenaillon; Claire Hoede; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

9.  Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island.

Authors:  Philip A Chan; Marissa B Reitsma; Allison DeLong; Bruce Boucek; Amy Nunn; Marco Salemi; Rami Kantor
Journal:  Infect Genet Evol       Date:  2014-04-08       Impact factor: 3.342

10.  Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Authors:  Bernard Masquelier; Dominique Breilh; Didier Neau; Sylvie Lawson-Ayayi; Valérie Lavignolle; Jean-Marie Ragnaud; Michel Dupon; Philippe Morlat; F Dabis; H Fleury
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.